

United Kingdom Prostate Cancer Therapeutics Market By Treatment (Hormonal Therapy (Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists, Hormone-Releasing Hormone (LHRH) Agonists, Anti- Androgen), By End User (Hospital pharmacies, Retail pharmacies, Online pharmacies), By Region, Competition Forecast & Opportunities, 2018-2028F

<https://marketpublishers.com/r/UC162072D4ACEN.html>

Date: October 2023

Pages: 81

Price: US\$ 3,500.00 (Single User License)

ID: UC162072D4ACEN

Abstracts

The United Kingdom Prostate Cancer Therapeutics Market is anticipated to grow significantly in the projected period of 2028. Prostate cancer is one of the most common types of cancer affecting men globally, including the United Kingdom. Over the years, significant progress has been made in the development of effective therapies to combat this disease. The United Kingdom has a robust healthcare system that prioritizes cancer care, including prostate cancer. According to the World Cancer Research Fund, 55,068 new prostate cancer cases were reported in the United Kingdom in 2019, with a one-year survival rate of 97.2% and a five-year survival rate of 87.9%. With a strong emphasis on early detection and timely treatment, the country has witnessed improved survival rates and better patient outcomes.

Prostate cancer therapeutics encompass a range of approaches, including surgery, radiation therapy, hormone therapy, and targeted therapies. In recent years, the UK has witnessed notable advancements in prostate cancer therapeutics. One significant breakthrough has been the development and approval of novel targeted therapies. These therapies aim to disrupt specific molecular pathways involved in prostate cancer progression, offering more personalized and precise treatment options for patients. Targeted therapies, such as androgen receptor inhibitors and PARP inhibitors, have demonstrated promising results in clinical trials, extending survival and improving the

quality of life for patients.

Furthermore, the advent of immunotherapy has opened new avenues in prostate cancer treatment. Immune checkpoint inhibitors, which unleash the body's immune system to recognize and attack cancer cells, have shown encouraging results in late-stage prostate cancer. Ongoing research and clinical trials are exploring the potential of combining immunotherapy with other treatment modalities to enhance efficacy, contributing to the growth of the Prostate Cancer Therapeutics Market in the United Kingdom.

In addition, the aging population is also driving demand for Prostate Cancer Therapeutics. As people age, their bodies become less efficient, and the chances of prostate cancer increase. This has led to an increase in demand for prostate cancer therapeutics that can help to recover from prostate cancer. According to the Office for National Statistics, the statistical results for 2021 show that the population of England and Wales has continued to age, and there are now more people than ever in older age categories. In comparison to 16.4% at the time of the previous census in 2011, almost 11 million people, or 18.6% of the total population, were 65 years of age or older. This comprised 527,900 individuals who were at least 90 years old.

Growing Prevalence of Prostate cancer will spur the Demand for Prostate Cancer Therapeutics

With the rising prevalence of this disease, the demand for effective prostate cancer therapeutics in the UK has witnessed a notable surge. Prostate cancer is the most commonly diagnosed cancer among men in the UK, and its prevalence is expected to continue increasing in the coming years. Prostate cancer is a malignant tumor that develops in the prostate gland, which is a part of the male reproductive system. Over the past few decades, the incidence of prostate cancer has been steadily increasing in the United Kingdom. Together with studies on migrants, the tendency of prostate cancer incidence to be significantly higher in Western nations (such as the UK) suggests that lifestyle and/or environmental factors, such as diet, may play a significant role in determining prostate cancer risk. However, there is currently a lack of knowledge regarding the lifestyle factors that may cause prostate cancer. Additionally, if a man has a first-degree relative (father or brother) who was diagnosed with prostate cancer at a young age, his risk of getting the disease rises. Factors such as an aging population, changing lifestyle patterns, and improved screening and diagnostic techniques have contributed to the rising number of prostate cancer cases. Age is a significant risk factor for prostate cancer, and as the UK population ages, the number of men at risk also

increases. The increasing life expectancy and changing demographics have played a pivotal role in the prevalence of prostate cancer. According to Prostate Cancer UK, prostate cancer claims the lives of one man every 45 minutes, or more than 12,000 men annually. On average, more than 52,000 men are given prostate cancer diagnoses each year, or 143 men each day. Treatment decisions depend on various factors such as the stage and aggressiveness of the cancer, the patient's overall health, and their preferences. The evolving landscape of prostate cancer treatment has witnessed the emergence of novel therapies, including immunotherapies and precision medicine approaches, which aim to improve patient outcomes and quality of life. Pharmaceutical companies and research institutions are investing heavily in the development of new prostate cancer therapeutics. Clinical trials are underway to evaluate the efficacy and safety of these novel treatment options, providing hope for better outcomes for prostate cancer patients, which is expected to propel the growth of the United Kingdom Prostate Cancer Therapeutics Market.

Expanding Novel Screening and Diagnostic Technologies Propel UK Prostate Cancer Therapeutics Market

The United Kingdom has been investing in the development of its health systems to improve patient care and streamline operations. The healthcare industry already utilizes robots, AI, and other automation tools. One of the most promising advancements in prostate cancer screening is the integration of biomarkers and genetic testing. Novel tests, such as the Prostate Health Index (phi) and 4Kscore, combine multiple biomarkers to provide a more accurate assessment of prostate cancer risk. These tests help reduce unnecessary biopsies and improve patient outcomes. Additionally, multiparametric magnetic resonance imaging (mpMRI) has gained significant traction in the United Kingdom for prostate cancer detection. mpMRI allows for high-resolution visualization of the prostate gland, aiding in the identification of suspicious lesions. By integrating mpMRI with targeted biopsies, clinicians can enhance the accuracy of cancer diagnosis while minimizing patient discomfort. Furthermore, expanding and developing public health initiatives, implementing new medical technologies, and making socioeconomic and educational advancements have significantly improved the country. As a result, patterns of morbidity and mortality, as well as other indicators of health status like average life expectancy at birth, have significantly improved. There has been a surge in research and development activities in the United Kingdom's Prostate Cancer Therapeutics market. According to the Office for National Statistics, in 2021, the total current healthcare expenditure increased by 7.1% in real terms, compared to 10.0% in 2020, after accounting for the effects of inflation on the economy as a whole.

Market Segmentation

United Kingdom Prostate Cancer Therapeutics Market is segmented into Treatment, End User, Region and Competitive Landscape. Based on Treatment, the market is divided into Hormonal Therapy, Immunotherapy, Targeted Therapy, Chemotherapy and Others. Based on End User, the Market is categorized into Hospital pharmacies, Retail pharmacies, Online pharmacies. Based on Region, the United Kingdom Prostate Cancer Therapeutics Market is segmented into Scotland, South-East, London, South-West, East-Anglia, Yorkshire & Humberside, and East Midlands.

Company Profiles

Johnson & Johnson, Astellas Pharma Inc, Ipsen Pharma, Sanofi, Bayer AG, AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Abbott, GlaxoSmithKline plc are some of the key players in the United Kingdom Prostate Cancer Therapeutics market.

Report Scope:

In this report, United Kingdom Prostate Cancer Therapeutics Market has been segmented into the following categories, in addition to the industry trends, which have also been detailed below:

United Kingdom Prostate Cancer Therapeutics Market, By Treatment:

Hormonal Therapy

Immunotherapy

Targeted Therapy

Chemotherapy

Others

United Kingdom Prostate Cancer Therapeutics Market, By End User:

Hospital pharmacies

Retail pharmacies

Online pharmacies

United Kingdom Prostate Cancer Therapeutics Market, By Region:

Scotland

South-East

London

South-West

East-Anglia

Yorkshire & Humberside

East Midlands

Competitive landscape

Company Profiles: Detailed analysis of the major companies in United Kingdom Prostate Cancer Therapeutics market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1. PRODUCT OVERVIEW

- 1.1. Market Definition
- 1.2. Scope of the Market
 - 1.2.1. Markets Covered
 - 1.2.2. Years Considered for Study
 - 1.2.3. Key Market Segmentations

2. RESEARCH METHODOLOGY

- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations

3. EXECUTIVE SUMMARY

- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, Trends

4. VOICE OF CUSTOMERS

5. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET OUTLOOK

- 5.1. Market Size & Forecast
 - 5.1.1. By Value
- 5.2. Market Share & Forecast
 - 5.2.1. By Treatment (Hormonal Therapy, Immunotherapy, Targeted Therapy, Chemotherapy, Others)
 - 5.2.2. By End User (Hospital pharmacies, Retail pharmacies, Online pharmacies)

- 5.2.3. By Company (2022)
- 5.2.4. By Region
- 5.3. Market Map
 - 5.3.1. By Treatment
 - 5.3.2. By End User
 - 5.3.3. By Region

6. UNITED KINGDOM PROSTATE CANCER HORMONAL THERAPY MARKET OUTLOOK

- 6.1. Market Size & Forecast
 - 6.1.1. By Value
- 6.2. Market Share & Forecast
 - 6.2.1. By Type (Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists, Anti-Androgen)
 - 6.2.2. By End User

7. UNITED KINGDOM PROSTATE CANCER CHEMOTHERAPY MARKET OUTLOOK

- 7.1. Market Size & Forecast
 - 7.1.1. By Value
- 7.2. Market Share & Forecast
 - 7.2.1. By Type (Taxotere, Jevtana)
 - 7.2.2. By End User

8. UNITED KINGDOM PROSTATE CANCER IMMUNOTHERAPY MARKET OUTLOOK

- 8.1. Market Size & Forecast
 - 8.1.1. By Value
- 8.2. Market Share & Forecast
 - 8.2.1. By End User

9. UNITED KINGDOM PROSTATE CANCER TARGETED THERAPY MARKET OUTLOOK

- 9.1. Market Size & Forecast
 - 9.1.1. By Value
- 9.2. Market Share & Forecast

9.2.1. By End User

10. MARKET DYNAMICS

10.1. Drivers

10.2. Challenges

11. MARKET TRENDS & DEVELOPMENTS

11.1. Mergers & Acquisitions

11.2. Recent Trends & Developments

11.3. New Type Launches

12. UNITED KINGDOM PROSTATE CANCER THERAPEUTICS MARKET: SWOT ANALYSIS

13. PORTERS FIVE FORCES ANALYSIS

13.1. Competition in the Industry

13.2. Potential of New Entrants

13.3. Power of Suppliers

13.4. Power of Customers

13.5. Threat of Substitute Types

14. PESTLE ANALYSIS

15. POLICY & REGULATORY LANDSCAPE

16. UNITED KINGDOM ECONOMIC PROFILE

17. COMPETITIVE LANDSCAPE

17.1. Johnson & Johnson

17.2. Astellas Pharma Inc

17.3. Ipsen Pharma

- 17.4. Sanofi
- 17.5. Bayer AG
- 17.6. AstraZeneca
- 17.7. Pfizer Inc.
- 17.8. Teva Pharmaceutical Industries Ltd.
- 17.9. Abbott
- 17.10. GlaxoSmithKline plc

18. STRATEGIC RECOMMENDATIONS

About us & Disclaimer

I would like to order

Product name: United Kingdom Prostate Cancer Therapeutics Market By Treatment (Hormonal Therapy (Luteinizing Hormone-Releasing Hormone (LHRH) Antagonists, Hormone-Releasing Hormone (LHRH) Agonists, Anti-Androgen), By End User (Hospital pharmacies, Retail pharmacies, Online pharmacies), By Region, Competition Forecast & Opportunities, 2018-2028F

Product link: <https://marketpublishers.com/r/UC162072D4ACEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/UC162072D4ACEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970